The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SRRK | +16.79% | -35.25% | -8.32% | +179% |
| S&P | +19.17% | +69.21% | +11.09% | +145% |
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$425.00K | -7.6% |
| Market Cap | $4.49B | 11.1% |
| Market Cap / Employee | $15.55M | 0.0% |
| Employees | 289 | 47.4% |
| Net Income | -$90,965.00K | -36.9% |
| EBITDA | -$91,471.00K | -32.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $323.53M | 81.9% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $103.37M | 74.2% |
| Short Term Debt | $5.55M | -3.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -85.97% | -23.3% |
| Return On Invested Capital | -48.29% | -2.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$75,528.00K | -52.5% |
| Operating Free Cash Flow | -$75,496.00K | -52.5% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.18 | 10.76 | 15.32 | 17.83 | -59.20% |
| Price to Tangible Book Value | 8.18 | 10.76 | 15.32 | 17.83 | -59.20% |
| Enterprise Value to EBITDA | -42.95 | -33.65 | -38.55 | -46.82 | -12.34% |
| Return on Equity | -106.7% | -172.1% | -218.0% | -123.1% | 48.39% |
| Total Debt | $63.14M | $61.53M | $110.08M | $108.92M | 67.24% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
